Shorter hormone therapy as effective as longer course for prostate cancer

09/25/2013 | U.S. News & World Report

Short-term hormone therapy after radiation treatment had a comparable effect on overall survival and disease-specific survival as longer-course therapy in men with intermediate-risk prostate cancer, according to a study presented at a meeting of the American Society for Radiation Oncology. In the study of 133 patients, disease-specific survival was 96% for both short- and long-term hormone therapy groups while 10-year overall survival was 61% in the shorter-course group and 65% in the long-term group.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR